AuditorMay 22, 2026, 06:02 PM
Calidi Biotherapeutics 2025 10-K Audit Report Raises Going Concern
AI Summary
Calidi Biotherapeutics announced that its Annual Report on Form 10-K for the year ended December 31, 2025, contained an audit report with an explanatory paragraph. This paragraph emphasized that the consolidated financial statements were prepared assuming the company will continue as a going concern. This disclosure is required by NYSE American Company Guide Section 610(b) and does not reflect any change or amendment to any of the company's filings for the fiscal year ended December 31, 2025.
Key Highlights
- Calidi Biotherapeutics' 2025 Annual Report on Form 10-K included an audit report with an explanatory paragraph.
- The paragraph emphasized that consolidated financial statements were prepared assuming the company will continue as a going concern.
- This disclosure is required by Section 610(b) of the NYSE American Company Guide.
- The release does not reflect any change or amendment to prior fiscal year 2025 filings.
Price Impact
More from CLDI